Popular weight-loss drug Wegovy goes on sale in China

Published On Nov 18, 2024, 11:34 PM

Novo Nordisk has launched its weight-loss drug Wegovy in China after receiving approval from local health authorities. This move provides access to an estimated 180 million people suffering from obesity in the country and intensifies competition with Eli Lilly's weight-loss treatment, which has not yet rolled out. The price of Wegovy in China is significantly lower than in the U.S., although patients will have to pay out-of-pocket as it is not yet covered by national healthcare insurance. Research indicates that patients can expect to lose over 10% of their body weight with Wegovy, although some may experience side effects and potential weight regain after cessation of treatment. The launch positions Novo Nordisk favorably in a major pharmaceutical market as the drug's popularity continues to grow globally, benefiting from high demand and celebrity endorsements.

Stock Forecasts

The introduction of Wegovy in China is likely to attract significant consumer interest and could lead to increased sales for Novo Nordisk, as there is a large patient population experiencing obesity. Given the drug's success in other markets and the substantial unmet need in China for obesity treatment, the outlook for Novo Nordisk appears very positive. The competitive pressure on Eli Lilly could also position Novo Nordisk as a leader in this lucrative market.

Related News

The excitement around the new weight-loss industry is overtaking other disease areas and portfolios for publicly traded companies.

LLY
NVO
AMGN

GLP-1 pills are the next frontier for the weight-loss market.

LLY
NVO
PFE

A new study found that weekly injections of 2.4 mg of semaglutide could lower the risk of deaths related to COVID-19, marking another potential benefit of these blockbuster drugs.